西黄胶囊联合TP方案对晚期非小细胞肺癌患者血清Foxp3、Ang-2水平的影响  

Clinical Efficacy of Xihuang Capsules Combined with TP Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

作　　者：刘小红[1] 杨庆辉[2] 张永恒[1] 王荦楠[2] 袁红昌 LIU Xiao-hong;YANG Qing-hui;ZHANG Yong-heng;WANG Luo-nan;YUAN Hong-chang(Department of Pharmacy,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang Henan 453100;Department of Oncology,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang Henan 453100)

机构地区：[1]河南省新乡医学院第一附属医院药学部,河南新乡453100 [2]河南省新乡医学院第一附属医院肿瘤科,河南新乡453100

出　　处：《世界中西医结合杂志》2022年第6期1214-1217,1222,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：2019年河南省医学科技攻关项目(LHGJ20190467)。

摘　　要：目的探讨西黄胶囊联合TP方案治疗晚期非小细胞肺癌患者的临床疗效。方法选取2017年6月—2019年6月期间新乡医学院第一附属医院收治的晚期非小细胞肺癌患者86例,采用随机摸球法分为对照组和治疗组,每组各43例。对照组采用TP方案化疗,治疗组在此基础上加用西黄胶囊治疗。两组患者均连续治疗42 d后,观察两组患者近期疗效及不良反应发生情况,同时观察两组患者治疗前后中医证候症状积分、血清叉头翼状螺旋转录因子3(Forkhead or winged helix transcription,Foxp3)、血管生成素-2(Angiopoietin-2,Ang-2)、美国东部肿瘤协作组体能状况(Eastern cooperative oncology group performance status,ECOGPS)评分变化。结果治疗后治疗组有效率为46.51%、疾病控制率为83.72%,与对照组有效率25.38%、疾病控制率65.12%比较,差异有统计学意义(P<0.05)。治疗后,两组患者咳嗽、气短、胸闷、出汗、乏力、畏寒肢冷、腰膝酸软积分及总分较治疗前均降低,差异有统计学意义(P<0.05);且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清Foxp3、Ang-2水平较治疗前明显降低,差异有统计学意义(P<0.05);且治疗组低于对照组,差异有统计学意义(P<0.05)。治疗后两组ECOGPS评分均较治疗前降低,差异有统计学意义(P<0.05);且治疗组低于对照组(P<0.05)。治疗组发热(30.23%)、恶心呕吐(30.23%)、血小板减少(34.88%)、白细胞减少(41.86%)及肝肾功能损伤(30.23%)发生率与对照组(53.49%、60.47%、55.81%、48.84%、44.19%)比较,差异有统计学意义(P<0.05)。结论西黄胶囊联合TP方案治疗NSCLC的效果显著,能明显改善患者临床症状及体能状况,减轻化疗毒副反应,并降低血清Foxp3、Ang-2表达水平发挥抗癌作用。Objective To investigate the clinical efficacy of Xihuang Capsules combined with TP regimen in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods Eighty-six patients with advanced NSCLC admitted to the First Affiliated Hospital of Xinxiang Medical Universityfrom June 2017 to June 2019 were randomly divided into a control group and a treatment group by a random ball test,with 43 cases in each group.All patients were treated with chemotherapy following the TP regimen,while those in the treatment group received additional Xihuang Capsules.Patients in both groups were treated continuously for 42 days.The short-term efficacy and the incidence of adverse reactions in the two groups were observed.The changes intraditional Chinese medicine(TCM)syndrome scores,serum forkhead/winged helix transcription(Foxp3),angiopoietin-2(Ang-2),and Eastern Cooperative Oncology Group Performance Status(ECOGPS)scores before and after treatment in the two groups were recorded.Results The effective rate(46.51%)and disease control rate(83.72%)of the treatment group were higher than those(25.38%and 65.12%)of the control group(P<0.05).After treatment,the scores of cough,shortness of breath,chest tightness,sweating,fatigue,aversion to cold,cold limbs,and soreness and weakness of waist and knees in the two groups,as well as the total scores were all lower than those before treatment(P<0.05),and the treatment group was lower than the control group(P<0.05).Aftertreatment,the levels of serum Foxp3 and Ang-2 in the two groups were lower than those before treatment(P<0.05),and the treatment group was lower than the control group(P<0.05).After treatment,the ECOGPS scores of the two groups decreased as compared with those before treatment(P<0.05),and the treatment group was lower than the control group(P<0.05).The incidence rates of fever(30.23%),nausea and vomiting(30.23%),thrombocytopenia(34.88%),leukopenia(41.86%),and liver and kidney function damage(30.23%)in the treatment group were higher than those(53.49%,60.47%,55

关 键 词：西黄胶囊 TP方案 晚期非小细胞肺癌 叉头翼状螺旋转录因子3(forkhead or winged helix transcription Foxp3) 血管生成素-2(angiopoietin-2 Ang-2) 

分 类 号：R734.2[医药卫生—肿瘤]